Evidence map›Paper›PMID 30448285›Full record

ArticleNeurobiology of disease2019

Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.

Andrew E Arrant, Anthony J Filiano, Aashka R Patel, Madelyn Q Hoffmann, Nicholas R Boyle, Shreya N Kashyap, Vincent C Onyilo, Allen H Young, Erik D Roberson

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Targeting Progranulin as an Immuno-Neurology Therapeutic Approach.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Andrew E ArrantDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Anthony J FilianoDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Aashka R PatelDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Madelyn Q HoffmannDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Nicholas R BoyleDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Shreya N KashyapDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Vincent C OnyiloDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Allen H YoungDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Erik D RobersonDepartments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL, United States. Electronic address: eroberson@uabmc.edu.
University of Alabama at Birmingham · US

Funding

UAB Neuroscience Core CenterP30NS047466 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HABLITZ, JOHN J. · 2005 to 2019
$8.5M
Mechanisms for the Benefit of Tau Reduction in Alzheimer Disease ModelsR01NS075487 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROBERSON, ERIK D · 2011 to 2015
$1.6M
Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin MutationsK99AG056597 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ARRANT, ANDREW EMMETT · 2017 to 2018
$271k
Mechanisms of frontotemporal dementia like behavior in progranulin deficient miceF32NS090678 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ARRANT, ANDREW EMMETT · 2015 to 2015
$55k
NIA NIH HHS K99 AG056597NINDS NIH HHS F32 NS090678NINDS NIH HHS P30 NS047466NINDS NIH HHS R01 NS075487
6 · The paper itself

Abstract

Loss-of-function mutations in progranulin (GRN), most of which cause progranulin haploinsufficiency, are a major autosomal dominant cause of frontotemporal dementia (FTD). Individuals with loss-of-function mutations on both GRN alleles develop neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder. Progranulin is a secreted glycoprotein expressed by a variety of cell types throughout the body, including neurons and microglia in the brain. Understanding the relative importance of neuronal and microglial progranulin insufficiency in FTD pathogenesis may guide development of therapies. In this study, we used mouse models to investigate the role of neuronal and microglial progranulin insufficiency in the development of FTD-like pathology and behavioral deficits. Grn

Indexed as

AnimalsBehavior, AnimalBrainFemaleFrontotemporal DementiaGliosisLipofuscinMaleMice, Inbred C57BLMice, KnockoutMicrogliaNeuronsProgranulinsSocial BehaviorGrn protein, mouseLipofuscinProgranulinsBehaviorFrontotemporal dementiaLysosomeMicrogliaNeuronNeuronal ceroid lipofuscinosisPathologyProgranulin

Identifiers

PMID30448285
PMCPMC6363848
OpenAlexW2901692703

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.